June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Automated quantification of retinal fluid and its impact on treatment outcomes in the FLUID study
Author Affiliations & Notes
  • Christoph Grechenig
    Department of Ophthalmology and Optometrics, Vienna, Austria
  • Jennifer Joan Arnold
    Marsden Eye Specialists, New South Wales, Australia
  • Hrvoje Bogunovic
    Department of Ophthalmology and Optometrics, Vienna, Austria
  • Robyn H Guymer
    Centre for Eye Research Australia, Victoria, Australia
  • Amir Sadeghipour
    Department of Ophthalmology and Optometrics, Vienna, Austria
  • Bianca S S. Gerendas
    Department of Ophthalmology and Optometrics, Vienna, Austria
  • Gregor Sebastian Reiter
    Department of Ophthalmology and Optometrics, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Department of Ophthalmology and Optometrics, Vienna, Austria
  • Footnotes
    Commercial Relationships   Christoph Grechenig, None; Jennifer Arnold, None; Hrvoje Bogunovic, None; Robyn Guymer, Apellis (C), Bayer (C), Novartis (C), Roche (C); Amir Sadeghipour, None; Bianca S Gerendas, IDx (F), Novartis (C), Roche (C); Gregor Reiter, None; Ursula Schmidt-Erfurth, Novartis (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3507. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christoph Grechenig, Jennifer Joan Arnold, Hrvoje Bogunovic, Robyn H Guymer, Amir Sadeghipour, Bianca S S. Gerendas, Gregor Sebastian Reiter, Ursula Schmidt-Erfurth; Automated quantification of retinal fluid and its impact on treatment outcomes in the FLUID study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3507.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the association of retinal fluid quantities with treatment outcomes in neovascular age-related macular degeneration (nAMD) by implementing artificial intelligence (AI) using data from the FLUID study. The FLUID study assessed the efficacy of a treat and extend (T&E) protocol: In one arm, treatment was extended while tolerating subretinal fluid (SRF) up to 200μm of height at the foveal center, whereas the other arm did not tolerate any SRF.

Methods : Subjects with nAMD undergoing treatment with ranibizumab over 24 months using two different T&E protocols were assessed via spectral domain optical coherence tomography (SD-OCT) imaging and best corrected visual acuity (BCVA). AI-based image analysis tools were used to detect and quantify SRF and intraretinal fluid (IRF) on SD-OCT. Subgroups of patients whom only showed either SRF or IRF alone at baseline were defined to compare BCVA at month 12 and 24 between both T&E protocols. Similarly, patients who gained 10 or 15 letters or more and patients who lost 10 or 15 letters or more were analyzed to compare fluid quantities between both T&E protocols at month 12 and 24. Analysis outcomes were BCVA and SRF/IRF volume in the total central 1mm and 6mm. Groups were compared using Mann-Whitney U test.

Results : A total of 82 patients who completed the FLUID study were analyzed. Comparing both T&E protocols (SRF tolerant and intolerant group), SRF/IRF volumes in the total central 1mm and 6mm were statistically not significantly different for the patients who gained or lost 10 or 15 letters or more at month 12 and month 24 (n=56, p>0.05). There was also no significant difference in BCVA at month 12 and 24 between both T&E protocols in patients showing either SRF or IRF alone at baseline (n=26, p>0.05). Comparing SRF/IRF volumes in the total central 1mm and 6mm after the first treatment with ranibizumab did not show a significant difference between patients who lost or gained 10 or 15 letters or more (all p>0.05).

Conclusions : AI-based image analyses provide a reliable tool to assess the quantitative impact of retinal fluid on treatment outcomes and supports patient-oriented decisions in nAMD therapy. By using AI we were able to show that despite this difference in SRF tolerance in the FLUID study, there was no difference in BCVA outcomes.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×